We are live on ! Find out more
COYA icon

Coya Therapeutics
COYA

21 hedge funds and large institutions have $20.7M invested in Coya Therapeutics in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 2

279% more capital invested

Capital invested by funds: $5.45M → $20.7M (+$15.2M)

40% more funds holding

Funds holding: 15 → 21 (+6)

13.91% more ownership

Funds ownership: 14.24% → 28.14% (+14%)

Holders
21
Holders Change
+6
Holders Change %
+40%
% of All Funds
0.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
10
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GC
Greenlight Capital
New York
+$4.47M
2
ACM
AIGH Capital Management
Maryland
+$2.75M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$460K
4
PCM
Potomac Capital Management
New York
+$117K
5
Citadel Advisors
Citadel Advisors
Florida
+$92K

Top Sellers

Rank Fund Capital Flow
1
WVP
Worth Venture Partners
New Jersey
-$229K
2
BlackRock
BlackRock
New York
-$1.35K
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
1
Greenlight Capital
New York
$9.44M +$4.47M +805,959 +172%
ACM
2
AIGH Capital Management
Maryland
$7.38M +$2.75M +496,183 +93%
CM
3
CM Management
Florida
$741K – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$720K +$460K +82,948 +584%
WVP
5
Worth Venture Partners
New Jersey
$687K -$229K -41,339 -31%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$685K +$30K +5,400 +6%
PCM
7
Prelude Capital Management
New York
$265K – – –
BlackRock
8
BlackRock
New York
$161K -$1.35K -244 -1%
PCM
9
Potomac Capital Management
New York
$156K +$117K +21,101 New
Citadel Advisors
10
Citadel Advisors
Florida
$123K +$92K +16,592 New
MCP
11
Mirador Capital Partners
California
$120K +$1.19K +214 +1%
Northern Trust
12
Northern Trust
Illinois
$110K +$82.5K +14,873 New
TRCT
13
Tower Research Capital (TRC)
New York
$24.8K +$6.9K +1,243 +59%
UBS Group
14
UBS Group
Switzerland
$18.4K +$13.8K +2,479 New
Morgan Stanley
15
Morgan Stanley
New York
$7.41K +$2.77K +499 +100%
TWM
16
Tradition Wealth Management
Minnesota
$6K – – –
Royal Bank of Canada
17
Royal Bank of Canada
Ontario, Canada
$2K +$599 +108 +107%
TAM
18
Tucker Asset Management
Colorado
$1.48K +$1.11K +200 New
Wells Fargo
19
Wells Fargo
California
$482 +$22 +4 +7%
JP Morgan Chase
20
JP Morgan Chase
New York
$482 +$333 +60 +1,200%
Bank of America
21
Bank of America
North Carolina
$74 +$55 +10 New

COYA Hedge Fund Activity: Q4 2023 in Review

21 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Coya Therapeutics (COYA) for Q4 2023, worth a combined $20.7M — up 279% from $5.45M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new COYA positions and 0 closed out — a net gain of 6 holders — while 10 added to existing stakes and 2 trimmed.

The largest buyer was Greenlight Capital, adding an estimated $4.47M. The largest seller was Worth Venture Partners, cutting an estimated $229K.

  • 21 institutional investors held Coya Therapeutics (COYA) as of Q4 2023, up from 15 in Q3 2023.
  • Funds reported $20.7M of Coya Therapeutics stock for Q4 2023, up 279% quarter-over-quarter.
  • 6 funds opened new Coya Therapeutics positions in Q4 2023 and 0 closed out, a net change of +6 holders.
  • The largest Coya Therapeutics buyer in Q4 2023 was Greenlight Capital, an estimated $4.47M added.
  • The largest Coya Therapeutics seller in Q4 2023 was Worth Venture Partners, an estimated $229K sold.

Based on aggregated 13F filings for Q4 2023.